Scil Technology – a New German Biopharmaceutical Company – is Launched by the Scil Group Irina Staatz-Granzer is Named Managing Director

MARTINSRIED, Germany

, October 28, 2003 - 

Scil Technology, a new company focused on the development of tissue regeneration products, was officially launched today. The Company was created from the Scil Group and has one shareholder, BioNet Holding GmbH. At the same time, Scil Technology announced that it has appointed Dr Irina Staatz-Granzer as Managing Director of the new Company.

Scil Technology will develop innovative products for bone and cartilage regeneration in dentistry and orthopaedics, combining synthetic, resorbable scaffolds with bone and cartilage specific proprietary growth factors. The Company has a proprietary protein coating technology that ensures a homogenous and stable coating of growth factor on various matrices and implants, allowing for controlled release of the growth factors in vivo.

Dr Irina Staatz-Granzer, Managing Director of Scil Technology, commented:
“I am delighted to be taking on this challenging role within Scil Technology, a new company at the forefront of pioneering regenerative dental and orthopaedic biomaterials. With its experienced development team, Scil Technology starts its life well placed to become one of the leading regenerative companies in the world.”

Dr Staatz-Granzer has more than 15 years' industrial experience in the pharmaceutical industry. She joined the Scil Group in 2002 as Vice President of Business Development of Scil Biomedicals. Before joining Scil she served as Director of Business Development at Knoll later Abbott. Prior to that, she held leading management positions in analytical development, international marketing and business development at Hermal Kurt Herrmann, a former 100% subsidiary of Merck KGaA, later Boots Healthcare International.

Scil Technology is a subsidiary of Bionet Holding GmbH and is the major shareholder of Scil Proteins GmbH. Scil Technology is located in Martinsried/Munich.

About Scil Technology GmbH

Scil Technology is a private biopharmaceutical development company focused on dental and orthopaedic tissue regeneration with a particular emphasis on bone and cartilage repair. The Company’s lead therapeutic candidates are based on recombinant, highly specific human growth factors. These are combined with biodegradable biomaterials to generate local application forms. Scil Technology’s pipeline for dentistry includes products that are targeted at periodontal disease, dental implantology and maxillofacial surgery. Orthopaedic products are developed for spinal fusion, traumatic lesions of  bone and cartilage tissue  and osteoarthritis. Scil Technology has emerged from the Scil Group and is located in the biotechnology cluster in Martinsried, Germany.

For more information please visit: <link www.scil.com>http://www.scil.com

Contacts

Media relations:

Sue Charles, MA, MBA, CEO
Northbank Communications
t : +44 (0) 20 7886 8152
e: s.charles@northbankcommunications.com

Douglas Pretsell, Ph.D., Senior Account Manager
Northbank Communications
t : +44 (0) 20 7886 8158
e:  d.pretsell@northbankcommunications.com

At Scil Technology:

Dr Irina Staatz-Granzer, Managing Director
Scil Technology GmbH
t: +49 (0)89 85651824
e: irina.staatz@scil.com